Epiheart
Cardiac Micrograft Therapy device company for cardiac surgery patients with heart failure, based in Helsinki
Highlights
- New on EvolcAdded 2026-11-03
About Epiheart
EpiHeart is a medical device company developing and manufacturing devices for surgical administration of cardiac cell therapies. Its initial focus is Cardiac Micrograft Therapy™, with pre-clinical and clinical results cited for effects on ventricular wall structure and scar size in heart failure.
The company is conducting clinical studies and is open to collaboration with cardiac surgery units and distributors in the EU and US, including research and commercial partnerships on advanced cell and gene therapies that could be administered surgically. Its devices are manufactured in compliance with ISO 13485:2016.
EpiHeart is a University of Helsinki spin-off, founded in 2019 and based in Helsinki, Finland, where it works with the University of Helsinki, Helsinki University Hospital (HUS) and Aalto University. The company reports more than 10 years of research conducted on three continents and has a collaboration with the University of Edinburgh's Centre for Cardiovascular Science.
Product: Cardiac Micrograft Therapy devices for surgical administration of cardiac cell therapy during cardiac surgery.
Jobs at Epiheart
Leadership
- Esko Kankuri · Head of science, Co-FounderSource: company website
- Kai Kronström · CEO, Co-FounderSource: company website
More biotech & pharma companies
EstiMates
Statistical, data management and bioinformatics services for clinical trials and life science research sponsorsNew on EvolcExperimentica
Contract research for ophthalmic drug developers: preclinical eye disease models, in vivo testing and histology servicesNew on EvolcFaron Pharmaceuticals
Clinical-stage biopharma developing immunotherapies for cancer patients, led by bexmarilimab, an anti-Clever-1 antibodyNew on EvolcFermion
Pharmaceutical API development and manufacturing, with CDMO services for generic drug and NCE companiesNew on EvolcFinncure
Synthetic carrier particles for targeted drug delivery, developed for pharma and biotech partners in FinlandNew on EvolcFinnoflag
Microbial detection, research and biorefinery services for industry, health care and water utilities in FinlandNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Analytics 4High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.